Acceptance-Based Treatment for Prostate Cancer Distress
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Prostate cancer (PCa) is the most common type of cancer in men and the second leading cause of death in American men. Those diagnosed with localized prostate cancer encounter three sources of psychological distress: 1) diagnosis itself, 2) treatment decision making, and 3) the often life-altering side effects of treatment. In addition, patients who choose to undergo active surveillance which focuses on monitoring cancer in lieu of treatment, experience distress related to living with cancer. Acceptance and Commitment Therapy (ACT) is an established psychosocial intervention that has been used extensively for mental health treatment and has shown benefits for various chronic conditions. ACT is a behavioral intervention that focuses on tolerating distress and improving function. This pilot study is designed to test the feasibility of ACT for distress reduction and improved quality of life in patients recently diagnosed with early-stage, localized PCa.
| Condition | Intervention |
|---|---|
|
Early Stage Prostate Cancer |
Behavioral: Acceptance and Commitment Therapy |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | Pilot Study of an Acceptance and Commitment Therapy Workshop for Distress and Decision Making in Early Stage Prostate Cancer in Veterans |
- Number of dropouts [ Time Frame: 6 months ] [ Designated as safety issue: No ]Because this is a pilot study to determine feasibility, one of the primary outcomes is the number of participants who drop out of the active treatment arm.
- Number of refusals [ Time Frame: 6 months ] [ Designated as safety issue: No ]Because this is a pilot study to determine feasibility, one of the primary outcomes is the number of participants who refuse the active treatment arm.
- Hospital Anxiety and Depression Scale [ Time Frame: baseline, post intervention, 2 weeks post intervention, 3 months post intervention ] [ Designated as safety issue: No ]
- Memorial Anxiety Scale for Prostate Cancer [ Time Frame: baseline, post intervention, 2 weeks post intervention, 3 months post intervention ] [ Designated as safety issue: No ]
| Enrollment: | 24 |
| Study Start Date: | March 2011 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Acceptance and Commitment Therapy
Group-based behavioral workshop to address cancer-related distress
|
Behavioral: Acceptance and Commitment Therapy
group-based behavioral workshop to address cancer-related distress
|
| No Intervention: treatment as usual |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Localized prostate cancer in Stages I or II
- Ability to give informed consent
- Age 18 to 80 years old
- Willingness to come in for a day long intervention
Exclusion Criteria:
- Acute psychosis
- Suicidal ideation
- Homicidal ideation
- Active substance abuse
- Dementia
Contacts and Locations| United States, California | |
| VA San Diego Healthcare System | |
| San Diego, California, United States, 92161 | |
| Principal Investigator: | Niloofar Afari, PhD | San Diego Veterans Healthcare System |
More Information
No publications provided
| Responsible Party: | Veterans Medical Research Foundation |
| ClinicalTrials.gov Identifier: | NCT01594593 History of Changes |
| Other Study ID Numbers: | 110353 |
| Study First Received: | April 23, 2012 |
| Last Updated: | November 16, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Veterans Medical Research Foundation:
|
prostate cancer behavioral acceptance and commitment therapy distress |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013